CNBC Pro highlights the top performing stocks this week and analyzes whether the good times will continue.» Read More
Stocks ended higher Tuesday, snapping a three-day losing streak, after strong earnings from Merck and a better-than-expected housing report lifted sentiment on the Street.
The health care sector today just went positive for 2009, making it the only major industry group to currently be in the green for this young year.
The Dow and S&P 500 fell on Monday as uncertainty about the Obama administration's plan to stem bank losses dragged down financial shares.
Call options are heating up in Amgen, which is up slightly Monday in a sluggish market. As AMGN trades at about $55.20 the Febuary 57.5 and 60 calls are drawing a few nibbles, but most of today's action involves the Febuary 65 calls. What's it mean?
Thomas writes, "Is it time to short the XLF? " Also Yog asks, "what are the traders thoughts on Amgen after their earnings report?"
Stocks climbed on Tuesday, with the S&P 500 and the Nasdaq up for a third straight day after encouraging news on the earnings front...
Investors can’t help but wonder what’s the best way to play Pharma after Pfizer said it would buy rival Wyeth for $60 billion, a 20% premium!
In this Web Extra, the traders reveal how they're gaming earnings from McDonald's, Amgen, Caterpillar, Starbucks as well as the Fed Meeting and much more!
Dow component and giant healthcare company--you really can't lump it in with big pharma because it sells drugs, medical devices and consumer products--Johnson & Johnson reported earnings this morning.
Some call it the Super Bowl of healthcare. We’re talking about the JP Morgan Healthcare Conference kicking off Monday and it could move stocks.
Following are the year’s biggest winners and losers. Find out why shares of McDonald’s and Gilead Sciences popped while General Motors and Citigroup dropped.
BlackRock vice chairman and global chief investment officer of equities Bob Doll says it's time to re-introduce risk into portfolios.
The week ended with a stunningly bad November jobs report, indicating that the economy is getting much worse much faster than expected, and suggesting that the recession will be especially deep and prolonged. It was a grim end to a volatile week, beginning with a huge loss on Monday, but CNBC guests continued to encourage investors to buy stocks, saying now is the time to position oneself for the recovery and take advantage of valuations.
The stock market was far off its morning lows, coming close to turning positive, as investors shook off a handful of weak economic reports and snapped up biotech shares and other defensive plays.
Look for M&A activity—big and small—a pair of breakthrough drugs and the prospect of government price controls.
The Thanksgiving-week rally took the markets up 10 percent, and with a 28-percent gain, financials outperformed just about everything else. BlackRock's Bob Doll sees investors cashing in on those gains this week, and recommends a move to more defensive stocks.
One of the weapons widely used to fight cholesterol might be more powerful than previously believed. Is there a trade here?
While on the elliptical at the gym the other night I was watching one network newscast and the person on the machine next to me was watching another one.
In this Web Extra find out why investors who are attempting to battle the bear with biotech are keeping a close eye on Amgen..